Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13203198 | 1.00 | HTT (0.38) | HTTEPHX2MEN1NPC1MAPT | |
| SCHEMBL14267884 | 1.00 | HTT (0.38) | HTTEPHX2MEN1NPC1MAPT | |
| SCHEMBL22704482 | 0.91 | HTT (0.41) | HTTEPHX2KMT2A | |
| SCHEMBL22343862 | 0.91 | HTT (0.38) | HTTEPHX2 | |
| SCHEMBL24989077 | 0.91 | HTT (0.38) | HTTEPHX2 | |
| SCHEMBL24900892 | 0.91 | HTT (0.38) | HTTEPHX2 | |
| SCHEMBL22704498 | 0.84 | HTT (0.36) | HTTKMT2A | |
| SCHEMBL25152712 | 0.84 | — | — | |
| SCHEMBL12599507 | 0.84 | — | — | |
| SCHEMBL23015868 | 0.82 | CYP1A2 (0.39) | HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400505-A1 | PEPTIDE-UREA DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND APPLICATION THEREOF | Bivision Pharmaceuticals, Inc (CN) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023173074-A2 | IMMUNOSTIMULANT-CYTOTOXIC CONJUGATE COMPOSITION AND METHODS FOR CANCER TREATMENT | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230242509-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION | 2023-08-03 | — | — | US | disclosed |
| WO-2023125627-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | LYNK PHARMACEUTICALS CO., LTD. (CN) | 2023-07-06 | — | — | WO | disclosed |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-07-14 | — | — | US | disclosed |
| WO-2022118186-A1 | SENOTHERAPEUTIC COMPOUND | BIONEXA S.R.L. (IT) | 2022-06-09 | — | — | WO | disclosed |
| EP-3971176-A1 | AROMATIC AMINE AR AND BET TARGETING PROTEIN DEGRADATION CHIMERA COMPOUND AND USE | Hinova Pharmaceuticals Inc. (CN) | 2022-03-23 | — | — | EP | disclosed |
| EP-3556752-B1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-05 | — | — | EP | disclosed |
| CN-108137557-B | Nrf2 modulators | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-09-07 | — | — | CN | disclosed |
| US-10988482-B2 | IRAK4 inhibitor and use thereof | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2021-04-27 | — | — | US | disclosed |
| US-7282516-B2 | 4-cyanopyrazole-3-carboxamide derivatives, preparation, and application thereof | SANOFI-AVENTIS (FR) | 2007-10-16 | — | — | US | disclosed |
| US-7282516-B2 | 4-cyanopyrazole-3-carboxamide derivatives, preparation, and application thereof | SANOFI-AVENTIS (FR) | 2007-10-16 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20070043060-A1 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | disclosed |
| US-20070043060-A1 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | HTT 55/4885EPHX2 4026/4885MEN1 4681/4885 |
| US-10988482-B2 | IRAK4 inhibitor and use thereof | IRAK4, IRAK1, IRAK2 | HTT 3705/4885EPHX2 3067/4885MEN1 3168/4885 |
| US-20230242509-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CRBN, AR, ESRRA | HTT 1138/4885EPHX2 4376/4885MEN1 632/4885 |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | HTT 3757/4885EPHX2 3756/4885MEN1 2401/4885 |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | HTT 48/4885EPHX2 3941/4885MEN1 4723/4885 |
| US-20070043060-A1 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | OXA1L, ARG2, CYP3A7 | HTT 3180/4885EPHX2 831/4885MEN1 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.